Mercy Halo test is being developed for high-risk lung cancer screening. Credit: kalhh from Pixabay.

Mercy BioAnalytics has raised $41m in Series A financing to accelerate the development of its lung cancer screening test platform, Mercy Halo.

Novalis LifeSciences led the oversubscribed financing round, while other participants included Hatteras Venture Partners, Sozo Ventures, iSelect Fund, American Cancer Society BrightEdge, and Broadway Angels.

Go deeper with GlobalData

Premium Insights

The gold standard of business intelligence.

Find out more

Related Company Profiles

View all

Under this round, the company also received strategic investments from Labcorp and Bruker as well as existing investors.

Mercy directors board member and Novalis LifeSciences partner Paul Meister said: “Mercy is taking a unique approach designed to address the challenges that have plagued early cancer detection liquid biopsy tests that seek to measure tumour-derived DNA.”

The Mercy Halo test platform is an easy-to-administer blood test for high-risk lung cancer screening.

See Also:

A portion of the funds for the test will also be allocated to accelerate clinical programmes in additional indications, including ovarian cancer.

How well do you really know your competitors?

Access the most comprehensive Company Profiles on the market, powered by GlobalData. Save hours of research. Gain competitive edge.

Company Profile – free sample

Thank you!

Your download email will arrive shortly

Not ready to buy yet? Download a free sample

We are confident about the unique quality of our Company Profiles. However, we want you to make the most beneficial decision for your business, so we offer a free sample that you can download by submitting the below form

By GlobalData
Visit our Privacy Policy for more information about our services, how we may use, process and share your personal data, including information of your rights in respect of your personal data and how you can unsubscribe from future marketing communications. Our services are intended for corporate subscribers and you warrant that the email address submitted is your corporate email address.

It is expected that the company will additionally use the Mercy Halo liquid biopsy platform technology for the development of a range of tests to facilitate the early detection of cancer.

The platform enables the simultaneous detection of multiple co-localised, cancer-related biomarkers on the surface of single extracellular vesicles derived from tumour cells.

The Mercy Halo test can be run on a low volume of serum or plasma with a simple PCR-based read-out due to the abundance of extracellular vesicles in circulation.

Mercy BioAnalytics CEO Dawn Mattoon said: “We believe the Mercy Halo testing platform is uniquely capable of delivering high-performing, broadly accessible cancer screening across all communities.

“A simple, inexpensive blood-based screening test could be a vital new tool to significantly increase patient engagement in lung cancer screening, creating the opportunity to save lives through early detection.”